Bio-Techne (TECH) Stock Review: Analyst Upgrades Point to Biotech Stability
Highlights
-
Bio-Techne carries a “Moderate Buy” consensus from 13 analysts, with an average price target of $70.58, implying about 15% upside.
-
Recent positive revisions include TD Cowen (Oct. 14, target raised from $65 to $70, Strong Buy), Evercore ISI (Oct. 7, $60 to $72, Buy), and RBC Capital (Sept. 3, upgraded from Hold to Buy with a $73 target).
-
Fiscal 2025 revenue increased 5.23% to $1.22 billion, while Q4 EPS of $0.53 exceeded the $0.50 consensus estimate.
-
There have been no analyst downgrades in the past 90 days; 42% of ratings are Strong Buy, reflecting confidence in the company’s proteomics growth.
Market Overview
Bio-Techne Corporation continues to show steady performance within the biotechnology research tools space. Recent trading reflects balanced investor sentiment, supported by consistent demand from academic, clinical, and pharmaceutical customers. The stock has demonstrated resilience relative to broader biotech indices, aided by recurring consumables revenue and growing adoption of spatial biology technologies. Its diversified exposure across pharma, diagnostics, and life sciences helps smooth cyclical demand swings.
AI Trading Strategy Snapshot
The TECH - AI Trading Agent with Corridor TP/SL 2%, 60min applies financial learning models to capture short-term signals typical of biotech earnings and milestone news. The strategy targets a 2% gain while limiting downside to 2%, maintaining a structured risk-reward profile. Back-testing suggests this approach aligns well with TECH’s moderate volatility, offering a systematic way to participate in momentum driven by earnings reports and analyst updates.
Developments Influencing Recent Price Action
TECH shares have traded in a consolidation range as investors weigh solid quarterly execution against a year-over-year decline in net income. Fiscal 2025 revenue rose to $1.22 billion, driven by expansion in Protein Sciences and traction in spatial biology platforms. Net income declined to $73.36 million, reflecting increased R&D investment and acquisition-related costs.
For Q4 fiscal 2025 (reported August 6), Bio-Techne posted EPS of $0.53, topping expectations, and revenue of $316.96 million, slightly above forecasts. Gross margin improved to 46%, benefiting from a favorable product mix. The initial post-earnings share response underscored confidence in margin management and ongoing demand for reagents and diagnostic partnerships.
Analyst sentiment has been a major tailwind. In addition to recent upgrades, Citigroup raised its rating from Hold to Strong Buy in August, increasing its target from $55 to $70. Overall, the analyst community’s stance highlights Bio-Techne’s leadership in proteomics and confidence in its long-term growth.
While macroeconomic factors such as inflation data and Federal Reserve signals have driven volatility across biotech, Bio-Techne’s business has been relatively insulated, with more than 85% recurring revenue. Broader biotech index swings have at times created entry opportunities rather than sustained pressure.
What to Watch Going Forward
Investors will focus on Q1 fiscal 2026 results, expected in early January 2026, with consensus estimates around $320 million in revenue and $0.55 EPS. For full-year fiscal 2026, analysts project $1.25 billion in revenue (+8.2%) and $1.97 EPS.
Key drivers to monitor include adoption of spatial biology platforms, growth in proteomics reagents, and progress within the Diagnostics segment. Broader sector catalysts—such as FDA approvals, M&A activity in research tools, and macroeconomic data—may influence sentiment, while capital return programs add an element of longer-term visibility.
Contributor
TECH in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 10, 2026
TECH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 38 cases where TECH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on TECH as a result. In 60 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
Following a +0.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where TECH advanced for three days, in 198 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 84 of 216 cases where TECH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 39%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 59 cases where TECH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TECH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.394) is normal, around the industry mean (26.780). P/E Ratio (62.513) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (2.110) is also within normal values, averaging (9.059). TECH has a moderately high Dividend Yield (0.004) as compared to the industry average of (0.000). P/S Ratio (9.346) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. TECH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TECH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biological products manufacturer
Industry Biotechnology
Advertisement